Hora Maninder 4

4 · NEKTAR THERAPEUTICS · Filed Apr 9, 2018

Form 4

Period: 2018-04-05

SVP Pharma Dev and Mfg

Transactions

Exercise/Conversion
Common Stock
2018-04-05$7.21/sh+20,000$144,200→ 100,261 total
Exercise/Conversion
Common Stock
2018-04-09$7.21/sh+9,498$68,481→ 89,759 total
Sale
Common Stock
2018-04-05$101.75/sh−20,000$2,035,000→ 80,261 total
Sale
Common Stock
2018-04-09$105.05/sh−9,498$997,765→ 80,261 total
Exercise/Conversion
Stock Option
2018-04-05−20,000→ 42,500 total
Exercise: $7.21From: 2016-02-08Exp: 2020-02-07→ Common Stock (20,000 underlying)
Exercise/Conversion
Stock Option
2018-04-09−9,498→ 33,002 total
Exercise: $7.21From: 2016-02-08Exp: 2020-02-07→ Common Stock (9,498 underlying)

Footnotes (4)

[F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
[F2]This number includes 6,500 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).
[F3]This transaction was executed in multiple trades at prices ranging from $100.26 - $103.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
[F4]This transaction was executed in multiple trades at prices ranging from $105.00 - $105.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Documents

1 file